QuVa Pharma, Inc. 2025-04-02 Health serious FDA
Health · FDA · Recall #FDA-D-0296-2025
fentaNYL Citrate PF 200 mcg/100 mL (2 mcg/ml) /0.125% Bupivacaine HCl 125 mg/100 mL (1.25… Recall
Issued April 2, 2025 · QuVa Pharma, Inc.
In April 2025, QuVa Pharma, Inc. recalled the fentaNYL Citrate PF 200 mcg/100 mL (2 mcg/ml) /0.125% Bupivacaine HCl 125 mg/100 mL (1.25…, a serious health recall reported by the FDA.
Compiled by Maya Ellison, RecallCheckr
What this means for you
Lack of Assurance of Sterility
What you should do
- 1 Stop using fentaNYL Citrate PF 200 mcg/100 mL (2 mcg/ml) /0.125% Bupivacaine HCl 125 mg/100 mL (1.25… right away.
- 2 Set it aside where it won't be used by mistake.
- 3 Contact QuVa Pharma, Inc. to arrange your voluntary. See the official notice below for contact details.
- 4 Keep the product until your remedy is fully processed. You may need it.
Official remedy (Voluntary):
Recall details
- Brand
- QuVa Pharma, Inc.
- Category
- Health
- Recall date
- April 2, 2025
- Units affected
- Not reported
- Sold at
- U.S. Nationwide
- Recall number
- FDA-D-0296-2025
- Made in
- United States
- Issuing agency
- FDA
In context
- QuVa Pharma, Inc. has 2 recalls in our database.
- We're tracking 3,576 Health recalls in our database.
- This is the 691st Health recall we've logged in 2025.